Erworbene Inhibitoren gegen Faktor XIII

R. Egbring; A. Kröniger; R. Seitz

doi:10.1055/s-0038-1656653

Hämostaseologie, Table of Contents

Hamostaseologie 1996; 16(03): 174-179
DOI: 10.1055/s-0038-1656653

Übersichtsarbeiten/Review Articles

Schattauer GmbH

Erworbene Inhibitoren gegen Faktor XIII

R. Egbring

¹Abteilung für Hämatologie und Onkologie, Klinikum der Philipps-Universität Marburg

,

A. Kröniger

¹Abteilung für Hämatologie und Onkologie, Klinikum der Philipps-Universität Marburg

,

R. Seitz

¹Abteilung für Hämatologie und Onkologie, Klinikum der Philipps-Universität Marburg

› Author Affiliations

Abstract

PDF Download

Zusammenfassung

Antikörper gegen FXIII sind extrem selten: Bisher wurden zwei Patienten mit angeborenem FXIII-Mangel und 21 vorher gerinnungsnormale Patienten beschrieben, die Hemmkörper gegen FXIII entwickelten. Häufigster Auslöser für erworbene FXIII-Hemmkörper, die eine defekte Fibrinvernetzung verursachen, ist die Langzeitanwendung bestimmter Medikamente. Die Blutungssymptomatik zeigt das gesamte Spektrum des schweren FXIII-Mangels. Sofern ein Medikament als Ursache des Hemmkörpers in Frage kommt, ist dieses sofort abzusetzen. Weiterhin sollte versucht werden, durch hochdosierte Gabe eines FXIII-Konzentrates den Inhibitor zu überspielen und damit eine Blutstillung zu erzielen

Schlüsselwörter

Faktor-Xlll-Inhibitor - Pathogenese - Blutungssymptomatik - Therapie

PDF (10553 kb)

References

LITERATUR
1 Board P, Coggan M, Miloszewski K. Identification of a point mutation in factor XIII A subunit deficiency. Blood 1992; 80: 937
2 Board PG, Losowsky MS, Miloszewski KJ. Factor XIII: inherited and acquired deficiency. Blood Rev 1993; 7: 229
3 Bonn H. Comparative studies on the fibrin stabilizing factors from human plasma, platelets and placentas. Ann New York Acad Sci 1972; 202: 256-72
4 Daly HM, Carson PJ, Smith JK. Intracerebral haemorrhage due to acquired factor XIII inhibitor successful response to factor XIII concentrate. Blood Coag Fibrinol 1991; 2: 507-14
5 Dempfle CE, Magez J, Röckel A. et al. Acquired factor XIII deficiency and substitution of factor XIII in exacerbated ulcerative colitis and Crohn's disease. In: Factor XIII. McDonagh J, Scitz R, Egbring R. (eds). Stuttgart, New York: Schattauer; 1993: 181-92
6 Donnet A, Trefouret S, Alessi ML. et al. Intradural hematoma of the foramen magnum associated with factor XIII deficiency. Rev Neurol 1994; 50: 164
7 Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilising factor deficiency. Thromb Diath Haemorr 1960; 5: 179-86
8 Egbring R, Kailing A, Kehl HG. et al. Disorders with severe aquired Factor XIII Deficiency; lack of synthesis or increased consumption (DIC). Efficacy of Factor XIII replacement in bleeding complications. In: Factor XIII. McDonagh J, Scitz R, Egbring R. (eds). Stuttgart, New York: Schattauer; 1993: 216
9 Egbring R, Klingemann HG, Gramse M, Havemann K. Factor XIII Deficiency in patients with septicemia. In: Factor XIII and Fibronectin. Egbring R, Klingemann HG. (eds). Marburg: Medizin Verlagsges; 1982: 91
10 Egbring R, Rohner I, Lerch L. et al. Bleeding complications in patients with heterozygous FXIII subunit A deficiency?. Blood Coagulation and Fibrinolysis 1995; 6: 329-53
11 Egbring R, Schmidt W, Fuchs G, Havemann K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977; 49: 219-31
12 Egbring R, Scitz R, Gürten GV. et al. Bleeding complications in heterozygotes with congenital factor XIII deficiency. In: Fibrinogen 3. Biochemistry, Biological Functions, Gene Regulation and Expression. Mosesson et al. (eds). Amsterdam: Elsevier; 1988: 341
13 Egbring R, Scitz R. Improved prognosis of fulminant hepatic failure (FHF) after plasma derivative replacement therapy. Enhanced proteolysis of hemostatic proteins confirmed by proteinase-inhibitor complex determination. Z Gastroenterol 1990; 28: 104-9
14 Ehrenforth S, Kreuz W. et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992; 339: 594-8
15 Fear JD, Miloszewski KJA, Losowsky MS. An acquired inhibitor of factor XIII with a qualitative abnormality of fibrin crosslinking. Acta Haematol 1984; 71: 304-9
16 Fiore PA, Ellis LD, Dameshek HL, Lewis JH. XIII inhibitor and antituberculous therapy (abstract). Clin Res 1971; 19: 418
17 Francis SW, Marder VJ. Rapid formation of large molecular weight α polymers in crosslinked fibrin induced by high factor XIII concentrations. J Clin Invest 1987; 80: 1459-63
18 Francis W, Marder F, Marder VJ. Increased resistance to plasmic degradation of fibrin with highly cross-linked polymer chains formed at high factor XIII concentrations. Blood 1988; 71: 1361-5
19 Fukue H, Anderson K, McPhedran P. et al. A unique factor XIII inhibitor to a fibrinbinding site on factor XIIIa. Blood 1992; 79: 65-74
20 Gailani D. An IgG inhibitor against Factor XIII: resolution of bleeding after plasma immune adsorption with staphylococcae protein A. Am J Med 1992; 92: 110-2
21 Galanakis DK, Ginzier EM, Fikrig SM. Monoclonal IgG Anticoagulants delaying fibrin aggregation in two patients with systemic Lupus erythematosus (SLE). Blood 1978; 52: 1037
22 Ghosh S, McEvoy P, McVerry BA. Idiopathic autoantibody that inhibits fibrin monomer polymerization. Br J Hematol 1983; 53: 65-72
23 Godal HC, Ly B. An inhibitor of activated factor XIII, inhibiting fibrin cross-linking but not incorporation of amine into casein. Scand J Haematol 1977; 19: 443-8
24 Graham JE, Yount WJ, Roberts HR. Immunochemical characterization of a human antibody to factor XIII. Blood 1973; 41: 661-9
25 Green D, Lechner K. A survey of 215 nonhemophilic patients with inhibitors to FXIII. Thromb Haemost 1981; 45: 200
26 Green D, Velasco PT, Lorand L. Factor XIII autoantibody inhibiting alpha-chain crosslinking of fibrin. Clin Res 1992; 40: 242a (abst.)
27 Henriksson P, Becker S, Lynch G, McDonagh J. Identification of intracellular Factor XIII in human monocytes and macrophages. J Clin Invest 1985; 76: 528-34
28 Henriksson P, McDonagh J, Villa M. Type I autioimmune inhibitor of factor XIII in a patient with congenital factor XIII deficiency. Thromb Haemost 1983; 50: 272
29 Hoots WK, Carrell NA, Wagner RH. et al. A naturally occurring antibody that inhibits fibrin polymerization. N Engl J Med 1981; 304: 857
30 Kamitsuji H. et al. Activity of blood coagulation factor XIII as a prognostic indicator in patients with Henoch-Schoenlein purpura. Eur J Pediatr 1987; 146: 519
31 Kamura T, Okamura T, Murakawa M. et al. Deficiency of coagulation factor XIII A subunit caused by the dinucleotide deletion at the 5 end of exon III. J Clin Invest 1992; 90: 315
32 Kiesselbach TH, Wagner RH. Demonstration of factor XIII in human megakaryozytes by a flourescent antibody technique. Ann New York Acad Sci 1972; 202: 318-28
33 Kröniger A, Scitz R, Schwerk WB. et al. Elastase induced factor XIII substitution in intestinal bleeding. Thromb Haemost 1993; 69 (06) 877
34 Krumdick R, Shaw DR, Huang ST. et al. Hemorrhagic disorder due to an isoniazidassociated acquired factor XIII inhibitor in a patient with Waldenström's macroglobulinemia. Am J Medicine 1991; 90 (05) 639-45
35 Lewis JH, Szeto IL, F, Ellis LD, Bayer WL. An acquired inhibitor to coagulation factor XIII. Johns Hopkins Med J 1967; 120: 401
36 Lewis JH. Hemorrhagic disease associated with inhibitors of fibrin cross-linkage. Ann NY Acad Sci 1972; 202: 213-9
37 Lopaciuk S, Bykowska K, McDonagh JM. et al. Differences between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest 1978; 61: 1196-203
38 Lorand L, Campell LK, Robertson BJ. Enzymatic coupling of isoniazid to proteins. Biochemistry 1972; 11: 434-8
39 Lorand L, Jackson A, Bruner-Lorand J. A pathological inhibitor of fibrin cross-linking. J Clin Invest 1968; 47: 268-73
40 Lorand L, Jacobson A, Lorand JB. A pathological inhibitor of fibrin cross-linking. J Clin Invest 1968; 47: 268-73
41 Lorand L, Jacobson A. Isonicotinic acid hydrazide as an inhibitor of transpeptidation: relevance for blood coagulation. Nature 1967; 216: 508-9
42 Lorand L, Maldonado N, Fradera J. et al. Haemorrhagic syndrome of autoimmune origin with a specific inhibitor against fibrin stabilizing factor (factor XIII). Br J Haematol 1972; 23: 17-27
43 Lorand L, Velasco PT, Rinne JR. et al. Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. Proc Natl Acad Sci USA 1988; 85: 232-6
44 Lorenz R, Heinmüller M, Classen M. et al. Substitution of factor XIII: A therapeutic approach to ulcerative colitis. Haemostasis 1991; 21: 5-9
45 Mandel EE, Gerhold WM. Plasma fibrin stabilizing factor: aquired deficiency in various disorders. Am J Clin Pathol 1969; 52: 547-56
46 Mary A, Achyuthan KE, Greenberg CS. b-Chains prevent the proteolytic inactivation of the a-chains of plasma Factor XIII. Biochim Biophys Acta 1988; 966: 328-35
47 McDevitt NB, McDonagh J, Taylor HL, Roberts HR. An acquired inhibitor to factor XIII. Arch Intern Med 1972; 130: 772-7
48 McDonagh J. Hereditary and acquired deficiencies of activated Factor XIII. In: Williams Hematology. Beutler E. et al. (eds). New York: Mc Graw-Hill; 1995: 1455-80
49 McKee PA, Schwartz ML, Pizzo SV, Hill RL. Crosslinking of fibrin by fibrin-stabilizing factor. Ann NY Acad Sci 1972; 202: 127
50 Mikkola H, Syrjala M, Rasi V. et al. Deficiency in the A subunit of coagulation factor XIII: two novel point mutations demonstrate different effects on transcript levels. Blood 1994; 84: 517
51 Mikkola H. Four novel mutations in deficiency of coagulation factor XIII: consequences to expression and structure of a subunit A. Blood 1996; 87: 141-51
52 Milner GR, Hold PJL, Bottomley J, Macivier JE. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol 1977; 30: 770-3
53 Muszbek L, Adany R, Szegedi G. et al. FXIII of blood coagulation in human monocytes. Thromb Res 1985; 37: 401-10
54 Nakamura S, Kato A, Sakata Y, Aoki N. Bleeding tendency by IgG inhibitor to factor XIII, treated successfully by cyclophosphamide. Br J Haematol 1988; 68: 313-9
55 Nussbaum M, Morse BS. Plasma fibrin stabilizing factor in various diseases. Blood 1964; 23: 669-78
56 Otis PT, Fernstein D. l, Rapaport S.l, Patch MJ. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy; clinical and biochemical observations. Blood 1974; 44: 771-80
57 Rasche H, Dietrich M, Gaus W, Schleyer M. Factor XIII activity and fibrin subunit structure in acute leukemia. Biomedicine 1974; 21: 61
58 Rosenberg RD, Colman RW, Lorand L. A new haemorrhagic disorder with a defective fibrin stabilization and cryofibrinogenaemia. Br J Haematol 1974; 26: 269-84
59 Sakata Y, Aoki N. Cross-linking of alpha2- plasmin inhibitor to fibrin by fibrin-stabilizing factor. Clin Invest 1980; 65: 290
60 Scitz R, Egbring R. Patients with septic shock. Biomedical Process 1992; 5: 27-8
61 Shires L, Gomperts ED, Bradlow BA. An acquired inhibitor to factor XIIIa case report. S Afr Med J 1979; 56: 70-2
62 Teruya I. et al. An inhibitor to FXIII with interacting with its activated catalytic subunit.
63 Tosetto A, Castaman G, Manotti C, Rodeghiero F. Characterization of an acquired inhibitor to FXIII. XX Internat Cong World Fed Hemophilia 1992; 18: 29 (abst)
64 Uchino R. et al. Regulation of extravascular fibrinolysis by factor XIII. Fibrinolysis 1991; 5: 93